Clinical Trial

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1b/2 study to investigate the efficacy and safety of alcestobart (LBL-007) plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and alcestobart in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.
Protocol Amendment History 32 amendments
This ClinicalTrials.gov record has been amended 32 times since 2022-11-01; most recent amendment 2026-07-21.
Status change: Recruiting → Active, Not Recruiting 2024-12-30
Status change: Active, Not Recruiting → Recruiting 2023-08-10
Status change: Recruiting → Active, Not Recruiting 2023-05-31
Status change: Not Yet Recruiting → Recruiting 2022-12-22
Trial Details
NCT Number NCT05609370
Lead Sponsor BeiGene
Conditions Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Enrollment 113 participants
Start Date 2023-01-29
Primary Completion 2025-05-23 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-23